View in EDS

Pharmacological strategies to enhance the response of hepatoblastoma to chemotherapy through MDR1 inhibition.

Saved in:
Bibliographic Details
Title: Pharmacological strategies to enhance the response of hepatoblastoma to chemotherapy through MDR1 inhibition.
Authors: Cives-Losada C; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain., Macias RIR; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain., Lozano E; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain., Zanatto L; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036, Barcelona, Spain., Sancho-Bru P; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036, Barcelona, Spain., Martinez-Chantar ML; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.; Liver Disease Laboratory, Center for Cooperative Research in Biosciences (CICbioGUNE), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain., Avila MA; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.; Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, 31008, Pamplona, Spain., Armengol C; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.; Childhood Liver Oncology Group, Translational Program in Cancer Research (CARE), Germans Trias i Pujol Research Institute (IGTP), 08916, Badalona, Spain., Cairo S; Champions Oncology, Rockville, MD, 20850, USA., Marin JJG; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain. jjgmarin@usal.es.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain. jjgmarin@usal.es., Briz O; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain. obriz@usal.es.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain. obriz@usal.es.
Source: Acta pharmacologica Sinica [Acta Pharmacol Sin] 2026 Aug; Vol. 47 (8), pp. 2254-2267. Date of Electronic Publication: 2026 Apr 23.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42026237
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pharmacological strategies to enhance the response of hepatoblastoma to chemotherapy through MDR1 inhibition.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Cives-Losada+C%22">Cives-Losada C</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Macias+RIR%22">Macias RIR</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Lozano+E%22">Lozano E</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Zanatto+L%22">Zanatto L</searchLink>; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Sancho-Bru+P%22">Sancho-Bru P</searchLink>; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Martinez-Chantar+ML%22">Martinez-Chantar ML</searchLink>; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.; Liver Disease Laboratory, Center for Cooperative Research in Biosciences (CICbioGUNE), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain.<br /><searchLink fieldCode="AU" term="%22Avila+MA%22">Avila MA</searchLink>; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.; Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, 31008, Pamplona, Spain.<br /><searchLink fieldCode="AU" term="%22Armengol+C%22">Armengol C</searchLink>; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.; Childhood Liver Oncology Group, Translational Program in Cancer Research (CARE), Germans Trias i Pujol Research Institute (IGTP), 08916, Badalona, Spain.<br /><searchLink fieldCode="AU" term="%22Cairo+S%22">Cairo S</searchLink>; Champions Oncology, Rockville, MD, 20850, USA.<br /><searchLink fieldCode="AU" term="%22Marin+JJG%22">Marin JJG</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain. jjgmarin@usal.es.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain. jjgmarin@usal.es.<br /><searchLink fieldCode="AU" term="%22Briz+O%22">Briz O</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain. obriz@usal.es.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain. obriz@usal.es.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100956087%22">Acta pharmacologica Sinica</searchLink> [Acta Pharmacol Sin] 2026 Aug; Vol. 47 (8), pp. 2254-2267. <i>Date of Electronic Publication: </i>2026 Apr 23.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100956087 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1745-7254 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216714083%22">16714083 </searchLink><i>NLM ISO Abbreviation: </i>Acta Pharmacol Sin <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42026237
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41401-026-01791-z
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2254
    Titles:
      – TitleFull: Pharmacological strategies to enhance the response of hepatoblastoma to chemotherapy through MDR1 inhibition.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cives-Losada C
      – PersonEntity:
          Name:
            NameFull: Macias RIR
      – PersonEntity:
          Name:
            NameFull: Lozano E
      – PersonEntity:
          Name:
            NameFull: Zanatto L
      – PersonEntity:
          Name:
            NameFull: Sancho-Bru P
      – PersonEntity:
          Name:
            NameFull: Martinez-Chantar ML
      – PersonEntity:
          Name:
            NameFull: Avila MA
      – PersonEntity:
          Name:
            NameFull: Armengol C
      – PersonEntity:
          Name:
            NameFull: Cairo S
      – PersonEntity:
          Name:
            NameFull: Marin JJG
      – PersonEntity:
          Name:
            NameFull: Briz O
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2026 Aug
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1745-7254
          Numbering:
            – Type: volume
              Value: 47
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Acta pharmacologica Sinica
              Type: main
ResultId 1